Laurus Labs Ltd. (IN:LAURUSLABS)
:LAURUSLABS
Want to see IN:LAURUSLABS full AI Analyst Report?
LAURUSLABS Stock Chart & Stats
₹1107.05
-₹1.35(-0.22%)
At close: 4:00 PM EST
₹1107.05
-₹1.35(-0.22%)
Day’s Range― - ―
52-Week Range₹573.20 - ₹1,144.50
Previous CloseN/A
Volume1.25M
Average Volume (3M)107.31K
Market Cap
₹601.13B
Enterprise Value₹623.34B
Total Cash (Recent Filing)₹633.80M
Total Debt (Recent Filing)₹22.12B
Price to Earnings (P/E)59.4
Beta1.03
Next Earnings
Apr 30, 2026EPS Estimate
4.97Next Dividend Ex-DateN/A
Dividend Yield0.15%
Share Statistics
EPS (TTM)4.70
Shares Outstanding539,856,570
10 Day Avg. Volume186,027
30 Day Avg. Volume107,314
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)7.23
Price to Sales (P/S)5.82
P/FCF Ratio-821.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,280.00Price Target Upside15.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)19.64
Revenue Forecast (FY)₹78.90B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained ~27% revenue growth indicates expanding commercial traction across APIs, FDF and CDMO lines. Given Laurus's global supply footprint and ARV exposure, this top-line momentum supports scale economics, reinvestment capacity and long-term contract credibility over months.
Gross Margin StrengthA strong gross margin reflects effective cost management and manufacturing efficiency in API and FDF production. Durable manufacturing economics help absorb pricing pressure in generics, support margin sustainability, and fund R&D and capacity expansion over the medium term.
Diversified Pharma Business ModelOperating across APIs, finished dosages and CDMO services reduces reliance on any single revenue source. Institutional ARV demand, global tender channels and service contracts provide recurring, structural revenue streams and lower single-customer concentration risk over months.
Bears Say
Negative Free Cash FlowNegative free cash flow driven by elevated capex constrains internal funding for operations or dividends and increases reliance on external financing. Persistent negative FCF can pressure liquidity and limit strategic flexibility across the next 2–6 months if capex remains high.
Rising Liabilities / Moderate LeverageA declining equity ratio and moderate leverage signal increasing liabilities relative to assets. Higher leverage reduces financial flexibility, raises interest exposure, and limits capacity for opportunistic investments or buffering regulatory/market shocks in the medium term.
Net Margin CompressionFalling net margins from rising expenses erode returns despite solid gross margins. If operating costs or SG&A pressures persist, profitability and ROE could remain depressed, constraining retained earnings for growth and weakening resilience over the coming quarters.
Laurus Labs Ltd. News
LAURUSLABS FAQ
What was Laurus Labs Ltd.’s price range in the past 12 months?
Laurus Labs Ltd. lowest stock price was ₹573.20 and its highest was ₹1144.50 in the past 12 months.
What is Laurus Labs Ltd.’s market cap?
Laurus Labs Ltd.’s market cap is ₹601.13B.
When is Laurus Labs Ltd.’s upcoming earnings report date?
Laurus Labs Ltd.’s upcoming earnings report date is Apr 30, 2026 which is in 2 days.
How were Laurus Labs Ltd.’s earnings last quarter?
Laurus Labs Ltd. released its earnings results on Jan 23, 2026. The company reported ₹4.7 earnings per share for the quarter, beating the consensus estimate of ₹3.675 by ₹1.025.
Is Laurus Labs Ltd. overvalued?
According to Wall Street analysts Laurus Labs Ltd.’s price is currently Undervalued.
Does Laurus Labs Ltd. pay dividends?
Laurus Labs Ltd. pays a Notavailable dividend of ₹0.8 which represents an annual dividend yield of 0.15%. See more information on Laurus Labs Ltd. dividends here
What is Laurus Labs Ltd.’s EPS estimate?
Laurus Labs Ltd.’s EPS estimate is 4.97.
How many shares outstanding does Laurus Labs Ltd. have?
Laurus Labs Ltd. has 539,856,570 shares outstanding.
What happened to Laurus Labs Ltd.’s price movement after its last earnings report?
Laurus Labs Ltd. reported an EPS of ₹4.7 in its last earnings report, beating expectations of ₹3.675. Following the earnings report the stock price went up 1.214%.
Which hedge fund is a major shareholder of Laurus Labs Ltd.?
Currently, no hedge funds are holding shares in IN:LAURUSLABS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Laurus Labs Ltd.
Laurus Labs Limited, together with its subsidiaries, engages in the development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company develops, manufactures, and sells APIs and advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C therapeutic areas. It also develops and manufactures oral solid formulations for ARVs, anti-diabetic, cardiovascular, PPIs, and central nervous system. In addition, the company provides contract development and manufacturing services for pharmaceutical companies; and manufactures and sells specialty ingredients used in the nutraceutical, dietary supplements, and cosmeceutical products. Further, it develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceutical field. The company was incorporated in 2005 and is based in Hyderabad, India.
LAURUSLABS Stock 12 Month Forecast
Average Price Target
₹1,280.00
▲(15.62% Upside)
Technical Analysis
Aurobindo Pharma Ltd
―
Divi's Laboratories Limited
―
Dr. Reddy's Laboratories Ltd.
―
Lupin Limited
―
Sun Pharmaceutical Industries Limited
―